Johnson & Johnson unveils first clinical data for prostate cancer drug JNJ-6143 at ESMO 2026
JNJ•Johnson & Johnson plans to present more than 25 solid-tumor abstracts at the 2026 ESMO Congress, including first clinical results for investigational prostate cancer drug JNJ-6143.
1. ESMO presentations
Johnson & Johnson said it will present more than 25 solid-tumor abstracts at the 2026 ESMO Congress, including safety and efficacy findings for JNJ-6143 that will guide dose selection. The company also plans to present Phase 3 PROTEUS results on perioperative Erleada versus surgery alone, initial OrigAMI-4 findings for Rybrevant Faspro with pembrolizumab and carboplatin, and an indirect comparison of Rybrevant Faspro monotherapy with real-world therapies.
